Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?

Literature DB >> 31576285

Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: worth the risk?

Hira Latif¹, Stephen V Liu².

Abstract

Year: 2019 PMID： 31576285 PMCID： PMC6685870 DOI： 10.21037/atm.2019.03.6

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

× No keyword cloud information.

15 in total

1. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors: Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal: Lancet Date: 2016-12-13 Impact factor: 79.321

2. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.

Authors: Roy S Herbst; Paul Baas; Dong-Wan Kim; Enriqueta Felip; José L Pérez-Gracia; Ji-Youn Han; Julian Molina; Joo-Hang Kim; Catherine Dubos Arvis; Myung-Ju Ahn; Margarita Majem; Mary J Fidler; Gilberto de Castro; Marcelo Garrido; Gregory M Lubiniecki; Yue Shentu; Ellie Im; Marisa Dolled-Filhart; Edward B Garon
Journal: Lancet Date: 2015-12-19 Impact factor: 79.321

3. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.

Authors: A Lisberg; A Cummings; J W Goldman; K Bornazyan; N Reese; T Wang; P Coluzzi; B Ledezma; M Mendenhall; J Hunt; B Wolf; B Jones; J Madrigal; J Horton; M Spiegel; J Carroll; J Gukasyan; T Williams; L Sauer; C Wells; A Hardy; P Linares; C Lim; L Ma; C Adame; Edward B Garon
Journal: J Thorac Oncol Date: 2018-06-01 Impact factor: 15.609

4. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation.

Authors: James Chih-Hsin Yang; Shirish M Gadgeel; Lecia VanDam Sequist; Chien-Liang Wu; Vassiliki A Papadimitrakopoulou; Wu-Chou Su; Joseph Fiore; Sanatan Saraf; Harry Raftopoulos; Amita Patnaik
Journal: J Thorac Oncol Date: 2018-12-04 Impact factor: 15.609

5. EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Authors: Justin F Gainor; Alice T Shaw; Lecia V Sequist; Xiujun Fu; Christopher G Azzoli; Zofia Piotrowska; Tiffany G Huynh; Ling Zhao; Linnea Fulton; Katherine R Schultz; Emily Howe; Anna F Farago; Ryan J Sullivan; James R Stone; Subba Digumarthy; Teresa Moran; Aaron N Hata; Yukako Yagi; Beow Y Yeap; Jeffrey A Engelman; Mari Mino-Kenudson
Journal: Clin Cancer Res Date: 2016-05-25 Impact factor: 12.531

6. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.

Authors: James Chih-Hsin Yang; Frances A Shepherd; Dong-Wan Kim; Gyeong-Won Lee; Jong Seok Lee; Gee-Chen Chang; Sung Sook Lee; Yu-Feng Wei; Yun Gyoo Lee; Gianluca Laus; Barbara Collins; Francesca Pisetzky; Leora Horn
Journal: J Thorac Oncol Date: 2019-02-11 Impact factor: 15.609

Review 7. The polarization of immune cells in the tumour environment by TGFbeta.

Authors: Richard A Flavell; Shomyseh Sanjabi; Stephen H Wrzesinski; Paula Licona-Limón
Journal: Nat Rev Immunol Date: 2010-07-09 Impact factor: 53.106

8. PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression.

Authors: Jai-Nien Tung; Po-Lin Lin; Yao-Chen Wang; De-Wei Wu; Chi-Yi Chen; Huei Lee
Journal: Oncotarget Date: 2017-12-08

9. Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib.

Authors: A J Schoenfeld; K C Arbour; H Rizvi; A N Iqbal; S M Gadgeel; J Girshman; M G Kris; G J Riely; H A Yu; M D Hellmann
Journal: Ann Oncol Date: 2019-05-01 Impact factor: 32.976

10. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.

Authors: Mark A Socinski; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Claudia Kelsch; Anthony Lee; Shelley Coleman; Yu Deng; Yijing Shen; Marcin Kowanetz; Ariel Lopez-Chavez; Alan Sandler; Martin Reck
Journal: N Engl J Med Date: 2018-06-04 Impact factor: 91.245

1 in total

Review 1. Engaging innate immunity for targeting the epidermal growth factor receptor: Therapeutic options leveraging innate immunity versus adaptive immunity versus inhibition of signaling.

Authors: Gabriele Hintzen; Holger J Dulat; Erich Rajkovic
Journal: Front Oncol Date: 2022-09-14 Impact factor: 5.738

1 in total